New combo therapy aims to fight rare, aggressive breast cancer

NCT ID NCT03598257

Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study is for people with inflammatory breast cancer, a rare and aggressive type, who have already had chemotherapy and surgery. It tests whether adding the drug olaparib to standard radiation therapy helps keep the cancer from coming back. About 300 participants will be randomly assigned to get radiation alone or radiation plus olaparib.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Olaparib (a PARP inhibitor drug taken by mouth)
What this could lead to: If it works, this could point toward a more effective treatment for inflammatory breast cancer by combining a targeted drug with standard radiation.
What could go wrong: This is a phase II trial, so results are still preliminary. The drug may not improve survival and could cause side effects like fatigue or blood problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2019

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients must have inflammatory breast cancer without distant metastases. All biomarker subtype groups (estrogen receptor \[ER\], progesterone receptor \[PR\], HER2) are eligible. Inflammatory disease will be defined per American Joint Committee on Cancer (AJCC) 8th edition with documentation by history/exam and pathology at the time of diagnosis. * All patients must have completed neoadjuvant chemotherapy prior to mastectomy. The chemotherapy regimen is at the discretion of the treating physician but it is recommended that it include at least 4 cycles of anthracycline and/or taxane-based therapy (plus targeted therapy for patients with HER2+ disease). Response to chemotherapy is not a criterion for eligibility (both complete responders and those with residual disease are eligible). Please note that although pathologic complete response (pCR) is not required or excluded, pCR status must be determined post-surgery prior to randomization. * All patients must have undergone modified radical mastectomy (with negative margins on ink) with pathologic nodal evaluation (from level I and II axillary lymph node dissection \[ALND\]) at least 3 weeks and no more than 12 weeks prior to randomization, unless they receive additional chemotherapy after mastectomy. Patients must not have gross residual tumor or positive microscopic margins after mastectomy. * Additional adjuvant chemotherapy after surgery is allowed at the discretion of the treating physician, either completed prior to randomization or planned for after completion of protocol treatment. If adjuvant chemotherapy is administered after mastectomy, the patient must be randomized at least 3 weeks but no more than 12 weeks after the last dose of adjuvant chemotherapy. * Patients must not have a history of radiation therapy to the ipsilateral chest wall and/or regional nodes. Prior radiation therapy to other body sites is allowed. * Patients must not be planning to receive any other investigational agents during radiation therapy. Prior therapy, including prior treatment with olaparib or other PARP inhibitor, is allowed. * Patients must not have a known hypersensitivity to olaparib or any of the excipients of the product. * Patients must not have unresolved or unstable grade 2 or greater toxicity (with the exception of alopecia) from prior administration of another investigational drug and/or prior anti-cancer treatment. * Patients must not be planning to receive strong or moderate CYP3A inhibitors or inducers while on olaparib treatment. Patients receiving strong or moderate CYP3A inhibitors must agree to discontinue use at least 2 weeks prior to receiving olaparib. Patients receiving strong or moderate CYP3A inducers must agree to discontinue use at least 5 weeks prior to receiving olaparib. * Patients must not be planning to receive live virus or live bacterial vaccines while receiving olaparib and during the 30 day follow up period * Patients must not be planning to receive any additional anti-cancer therapy (chemotherapy, endocrine therapy, immunotherapy, biological therapy or other novel agent) while receiving radiotherapy with or without study medication. If a patient is receiving concurrent anti-HER2 targeted therapies, they must not take these medications during the period of radiotherapy (with or without study drug) while enrolled on the study. * Patients must be \>= 18 years of age * Patients must have Zubrod performance status 0-2. * Absolute neutrophil count (ANC) \>= 1000/mm\^3 (within 28 days prior to registration) * Platelet count \>= 100,000/mm\^3 (within 28 days prior to registration) * Hemoglobin \>= 9.0 g/dL (after transfusion if required and within 28 days prior to registration) * Patients must have adequate renal function as evidenced by calculated creatinine clearance \>= 51 mL/min by Cockcroft-Gault equation, within 28 days prior to registration. * Total bilirubin =\< 1.5 x upper limit of normal (ULN) (within 28 days prior to registration) * Patients with documented Gilbert's disease may have bilirubin up to 2.5 mg/dL * Serum glutamic-oxaloacetic transaminase (SGOT) =\< 2.5 x ULN (within 28 days prior to registration) * Serum glutamate pyruvate transaminase (SGPT) =\< 2.5 x ULN (within 28 days prior to registration) * Alkaline phosphatase =\< 2.5 x ULN (within 28 days prior to registration) * Patients must not have a history of other prior malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years * Female patients must be postmenopausal or have a negative urine or serum pregnancy test within 14 days prior to registration. Female patients of childbearing potential (and male patients with female partners who are of childbearing potential or pregnant) who are sexually active, must agree to the use of two highly effective forms of contraception during protocol treatment and for 6 months following the last dose of olaparib. Note: The efficacy of hormonal contraceptives may be reduced if co-administered with olaparib. Male patients must agree not to donate sperm during protocol treatment and for 6 months after the last dose of olaparib. * Patients who are breastfeeding must agree to discontinue breastfeeding before receiving olaparib due to potential risk for adverse events in nursing infants secondary to treatment of the mother with olaparib. * Patients must not have active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia. * Patients must be able to swallow and retain oral medications and have no known gastrointestinal disorders likely to interfere with absorption of the study medication. * Patients must not have a history of a resting electrocardiography (ECG) indicating uncontrolled, potentially reversible cardiac conditions (such as unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, Fridericia's formula corrected QT interval \[QTcF\] prolongation \> 500 ms, electrolyte disturbances) or congenital long QCYP3T syndrome. * Patients must not have myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML. * Patient must not have had major surgery within 2 weeks of starting study treatments and patients must have recovered from any effects of any major surgery. * Patients must not have a history of uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan. * Patients must not have had previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT). * Patients must not have had whole blood transfusions in the last 120 days prior to randomization. * Patients must be offered the opportunity to participate in specimen submission for banking. * Note: Germline and somatic BRCA status (genetic testing) are planned for future correlative evaluation, in order to examine treatment and circulating tumor deoxyribonucleic acid (ctDNA) response as stratified by BRCA 1/2 mutational status. Since this is future planned correlative research, any mutational status results would not be returned to the patient or the treating physician. There is no Clinical Laboratory Improvement Act (CLIA)-certified clinical genetic testing being performed for patients as part of the S1706 study. A forthcoming revision or separate corelative sciences proposal would be submitted to and approved by National Cancer Institute (NCI) prior to conduct of any planned future translational medicine objectives. * Patients who can complete the patient-reported outcomes (PRO) Quality of Life (QOL) and PRO-CTCAE questionnaires in English must be offered the opportunity to participate in the optional PRO substudy. Patients who are not able to complete questionnaires in English need not be offered the opportunity to participate. * Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines. * As a part of the OPEN registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

inflammatory breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast inflammatory carcinoma

Contacts and locations

Locations

AdventHealth Littleton

Littleton, Colorado, 80122, United States
AdventHealth Parker

Parker, Colorado, 80138, United States
AdventHealth Porter

Denver, Colorado, 80210, United States
Alaska Oncology and Hematology LLC

Anchorage, Alaska, 99508, United States
Allan Blair Cancer Centre

Regina, Saskatchewan, S4T 7T1, Canada
Alta Bates Summit Medical Center-Herrick Campus

Berkeley, California, 94704, United States
Altru Cancer Center

Grand Forks, North Dakota, 58201, United States
Anchorage Associates in Radiation Medicine

Anchorage, Alaska, 98508, United States
Anchorage Oncology Centre

Anchorage, Alaska, 99508, United States
Ascension Via Christi Hospitals Wichita

Wichita, Kansas, 67214, United States
Atrium Medical Center-Middletown Regional Hospital

Franklin, Ohio, 45005-1066, United States
Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234, United States
Baptist Memorial Hospital and Cancer Center-Desoto

Southhaven, Mississippi, 38671, United States
Baptist Memorial Hospital and Cancer Center-Memphis

Memphis, Tennessee, 38120, United States
Baptist Memorial Hospital and Cancer Center-Oxford

Oxford, Mississippi, 38655, United States
Beebe Health Campus

Rehoboth Beach, Delaware, 19971, United States
Beebe South Coastal Health Campus

Millville, Delaware, 19967, United States
Benefis Sletten Cancer Institute

Great Falls, Montana, 59405, United States
Bethesda North Hospital

Cincinnati, Ohio, 45242, United States
Billings Clinic Cancer Center

Billings, Montana, 59101, United States
Bozeman Health Deaconess Hospital

Bozeman, Montana, 59715, United States
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)

Québec, Quebec, G1R 2J6, Canada
Cancer Center of Western Wisconsin

New Richmond, Wisconsin, 54017, United States
Cancer Centers of Southwest Oklahoma Research

Lawton, Oklahoma, 73505, United States
Capital Health Medical Center-Hopewell

Pennington, New Jersey, 08534, United States
Carle Cancer Center

Urbana, Illinois, 61801, United States
Carlisle Regional Cancer Center

Carlisle, Pennsylvania, 17015, United States
CaroMont Regional Medical Center

Gastonia, North Carolina, 28054, United States
Case Western Reserve University

Cleveland, Ohio, 44106, United States
Centro Comprensivo de Cancer de UPR

San Juan, 00927, Puerto Rico
Chelsea Hospital

Chelsea, Michigan, 48118, United States
Christiana Care Health System-Concord Health Center

Chadds Ford, Pennsylvania, 19317, United States
Clackamas Radiation Oncology Center

Clackamas, Oregon, 97015, United States
Corewell Health Beaumont Troy Hospital

Troy, Michigan, 48085, United States
Corewell Health Dearborn Hospital

Dearborn, Michigan, 48124, United States
Corewell Health Farmington Hills Hospital

Farmington Hills, Michigan, 48336, United States
Corewell Health Grand Rapids Hospitals - Butterworth Hospital

Grand Rapids, Michigan, 49503, United States
Corewell Health William Beaumont University Hospital

Royal Oak, Michigan, 48073, United States
Crossroads Cancer Center

Effingham, Illinois, 62401, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Decatur Memorial Hospital

Decatur, Illinois, 62526, United States
Desert Regional Medical Center

Palm Springs, California, 92262, United States
Doctor's Hospital of Laredo

Laredo, Texas, 78041, United States
Emory Saint Joseph's Hospital

Atlanta, Georgia, 30342, United States
Emory University Hospital Midtown

Atlanta, Georgia, 30308, United States
Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Epic Care Partners in Cancer Care

Emeryville, California, 94608, United States
Fairview Ridges Hospital

Burnsville, Minnesota, 55337, United States
Fairview Southdale Hospital

Edina, Minnesota, 55435, United States
Farmington Health Center

Farmington, Utah, 84025, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
Fremont - Rideout Cancer Center

Marysville, California, 95901, United States
Geauga Hospital

Chardon, Ohio, 44024, United States
Gene Upshaw Memorial Tahoe Forest Cancer Center

Truckee, California, 96161, United States
George Washington University Medical Center

Washington D.C., District of Columbia, 20037, United States
Gibbs Cancer Center-Pelham

Greer, South Carolina, 29651, United States
Good Samaritan Hospital - Cincinnati

Cincinnati, Ohio, 45220, United States
Grady Health System

Atlanta, Georgia, 30303, United States
Greater Baltimore Medical Center

Baltimore, Maryland, 21204, United States
Gulfport Memorial Hospital

Gulfport, Mississippi, 39502, United States
Gundersen Lutheran Medical Center

La Crosse, Wisconsin, 54601, United States
Guthrie Medical Group PC-Robert Packer Hospital

Sayre, Pennsylvania, 18840, United States
HSHS Saint Elizabeth's Hospital

O'Fallon, Illinois, 62269, United States
Helen F Graham Cancer Center

Newark, Delaware, 19713, United States
Hennepin County Medical Center

Minneapolis, Minnesota, 55415, United States
Henry Ford Health Providence Novi Hospital

Novi, Michigan, 48374, United States
Henry Ford Health Providence Southfield Hospital

Southfield, Michigan, 48075, United States
Hope Women's Cancer Centers-Asheville

Asheville, North Carolina, 28816, United States
Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112, United States
IU Health Central Indiana Cancer Centers-Fishers

Fishers, Indiana, 46037, United States
IU Health Methodist Hospital

Indianapolis, Indiana, 46202, United States
IU Health North Hospital

Carmel, Indiana, 46032, United States
IU Health West Hospital

Avon, Indiana, 46123, United States
Indiana University/Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202, United States
Iowa Methodist Medical Center

Des Moines, Iowa, 50309, United States
Jewish General Hospital

Montreal, Quebec, H3T 1E2, Canada
Katmai Oncology Group

Anchorage, Alaska, 99508, United States
LSU Health Sciences Center at Shreveport

Shreveport, Louisiana, 71103, United States
Lafayette Family Cancer Center-EMMC

Brewer, Maine, 04412, United States
Lehigh Valley Hospital - Muhlenberg

Bethlehem, Pennsylvania, 18017, United States
Lehigh Valley Hospital-Cedar Crest

Allentown, Pennsylvania, 18103, United States
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

Savannah, Georgia, 31405, United States
Logan Health Medical Center

Kalispell, Montana, 59901, United States
Los Angeles General Medical Center

Los Angeles, California, 90033, United States
Lovelace Medical Center-Saint Joseph Square

Albuquerque, New Mexico, 87102, United States
Lovelace Radiation Oncology

Albuquerque, New Mexico, 87109, United States
Marshfield Medical Center - Minocqua

Minocqua, Wisconsin, 54548, United States
Marshfield Medical Center - Weston

Weston, Wisconsin, 54476, United States
Marshfield Medical Center-EC Cancer Center

Eau Claire, Wisconsin, 54701, United States
Marshfield Medical Center-Marshfield

Marshfield, Wisconsin, 54449, United States
Marshfield Medical Center-Rice Lake

Rice Lake, Wisconsin, 54868, United States
Marshfield Medical Center-River Region at Stevens Point

Stevens Point, Wisconsin, 54482, United States
Mayo Clinic Health System-Eau Claire Clinic

Eau Claire, Wisconsin, 54701, United States
Mayo Clinic Health System-Franciscan Healthcare

La Crosse, Wisconsin, 54601, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
McFarland Clinic - Ames

Ames, Iowa, 50010, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
Memorial Health University Medical Center

Savannah, Georgia, 31404, United States
Memorial Medical Center-Las Cruces

Las Cruces, New Mexico, 88011, United States
Mercy Cancer Center-West Lakes

Clive, Iowa, 50325, United States
Mercy Hospital

Coon Rapids, Minnesota, 55433, United States
Mercy Hospital Oklahoma City

Oklahoma City, Oklahoma, 73120, United States
Mercy Hospital Saint Louis

St Louis, Missouri, 63141, United States
Mercy Hospital South

St Louis, Missouri, 63128, United States
Mercy Hospital Springfield

Springfield, Missouri, 65804, United States
Mercy Medical Center - Des Moines

Des Moines, Iowa, 50314, United States
Miami Valley Hospital North

Dayton, Ohio, 45415, United States
Miami Valley Hospital South

Centerville, Ohio, 45459, United States
Michigan Healthcare Professionals Pontiac

Pontiac, Michigan, 48341, United States
Mission Hope Medical Oncology - Santa Maria

Santa Maria, California, 93444, United States
Mission Hospital

Asheville, North Carolina, 28801, United States
Missouri Baptist Medical Center

St Louis, Missouri, 63131, United States
Mount Sinai Comprehensive Cancer Center at Aventura

Aventura, Florida, 33180, United States
Mount Sinai Medical Center

Miami Beach, Florida, 33140, United States
Munson Medical Center

Traverse City, Michigan, 49684, United States
MyMichigan Medical Center Saginaw

Saginaw, Michigan, 48601, United States
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

Jonesboro, Arkansas, 72401, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York, New York, 10032, United States
Nebraska Cancer Specialists/Oncology Hematology West PC - MECC

Omaha, Nebraska, 68114, United States
Nebraska Methodist Hospital

Omaha, Nebraska, 68114, United States
Northwestern University

Chicago, Illinois, 60611, United States
Odette Cancer Centre- Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N 3M5, Canada
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Palo Alto Medical Foundation Health Care

Palo Alto, California, 94301, United States
Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416, United States
PeaceHealth Southwest Medical Center

Vancouver, Washington, 98664, United States
Penrose-Saint Francis Healthcare

Colorado Springs, Colorado, 80907, United States
Pluta Cancer Center

Rochester, New York, 14623, United States
Prisma Health Cancer Institute - Eastside

Greenville, South Carolina, 29615, United States
Prisma Health Cancer Institute - Faris

Greenville, South Carolina, 29605, United States
Prisma Health Cancer Institute - Greer

Greer, South Carolina, 29650, United States
Prisma Health Cancer Institute - Seneca

Seneca, South Carolina, 29672, United States
Prisma Health Cancer Institute - Spartanburg

Boiling Springs, South Carolina, 29316, United States
ProMedica Flower Hospital

Sylvania, Ohio, 43560, United States
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital

Toledo, Ohio, 43606, United States
Providence Alaska Medical Center

Anchorage, Alaska, 99508, United States
Providence Portland Medical Center

Portland, Oregon, 97213, United States
Providence Saint Vincent Medical Center

Portland, Oregon, 97225, United States
Queen's Medical Center

Honolulu, Hawaii, 96813, United States
Regions Hospital

Saint Paul, Minnesota, 55101, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
Rush MD Anderson Cancer Center

Chicago, Illinois, 60612, United States
Rush-Copley Medical Center

Aurora, Illinois, 60504, United States
Sacred Heart Hospital

Pensacola, Florida, 32504, United States
Saint Alphonsus Cancer Care Center-Boise

Boise, Idaho, 83706, United States
Saint Alphonsus Cancer Care Center-Nampa

Nampa, Idaho, 83687, United States
Saint Francis Medical Center

Cape Girardeau, Missouri, 63703, United States
Saint Joseph's/Candler - Bluffton Campus

Bluffton, South Carolina, 29910, United States
Saint Luke's Hospital

Chesterfield, Missouri, 63017, United States
Salina Regional Health Center

Salina, Kansas, 67401, United States
San Juan Community Oncology Group

San Juan, 00917, Puerto Rico
Sanford Bismarck Medical Center

Bismarck, North Dakota, 58501, United States
Sanford Joe Lueken Cancer Center

Bemidji, Minnesota, 56601, United States
Sanford Roger Maris Cancer Center

Fargo, North Dakota, 58122, United States
Sanford USD Medical Center - Sioux Falls

Sioux Falls, South Dakota, 57117-5134, United States
Shaw Cancer Center

Edwards, Colorado, 81632, United States
Spartanburg Medical Center

Spartanburg, South Carolina, 29303, United States
Springfield Memorial Hospital

Springfield, Illinois, 62781, United States
Springfield Regional Cancer Center

Springfield, Ohio, 45504, United States
Sutter Solano Medical Center/Cancer Center

Vallejo, California, 94589, United States
Swedish Medical Center-First Hill

Seattle, Washington, 98122, United States
Tampa General Hospital

Tampa, Florida, 33606, United States
The Cancer Center of Hawaii-Liliha

Honolulu, Hawaii, 96817, United States
The Cancer Center of Hawaii-Pali Momi

‘Aiea, Hawaii, 96701, United States
The Don and Sybil Harrington Cancer Center

Amarillo, Texas, 79106, United States
The Valley Hospital - Luckow Pavilion

Paramus, New Jersey, 07652, United States
ThedaCare Regional Cancer Center

Appleton, Wisconsin, 54911, United States
TidalHealth Nanticoke / Allen Cancer Center

Seaford, Delaware, 19973, United States
Trinity Health Medical Center - Brighton

Brighton, Michigan, 48114, United States
Trinity Health Medical Center - Canton

Canton, Michigan, 48188, United States
Trinity Health Saint Joseph Mercy Hospital Ann Arbor

Ann Arbor, Michigan, 48106, United States
Trinity Health Saint Joseph Mercy Oakland Hospital

Pontiac, Michigan, 48341, United States
Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154, United States
UH Seidman Cancer Center at Firelands Regional Medical Center

Sandusky, Ohio, 44870, United States
UH Seidman Cancer Center at Lake Health Mentor Campus

Mentor, Ohio, 44060, United States
UH Seidman Cancer Center at Saint John Medical Center

Westlake, Ohio, 44145, United States
UH Seidman Cancer Center at Southwest General Hospital

Middleburg Heights, Ohio, 44130, United States
UH Seidman Cancer Center at UH Avon Health Center

Avon, Ohio, 44011, United States
UHHS-Chagrin Highlands Medical Center

Beachwood, Ohio, 44122, United States
UHHS-Westlake Medical Center

Westlake, Ohio, 44145, United States
UPMC Cancer Center at UPMC Horizon

Farrell, Pennsylvania, 16121, United States
UPMC Cancer Centers - Arnold Palmer Pavilion

Greensburg, Pennsylvania, 15601, United States
UPMC Hillman Cancer Center Erie

Erie, Pennsylvania, 16505, United States
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion

Mechanicsburg, Pennsylvania, 17050, United States
UPMC Memorial

York, Pennsylvania, 17408, United States
UPMC Pinnacle Cancer Center/Community Osteopathic Campus

Harrisburg, Pennsylvania, 17109, United States
USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
UT MD Anderson - League City

League City, Texas, 77573, United States
UT MD Anderson - Sugar Land

Sugar Land, Texas, 77478, United States
UT MD Anderson - The Woodlands

Conroe, Texas, 77384, United States
UT MD Anderson - West Houston

Houston, Texas, 77079, United States
UT MD Anderson Cancer Center

Houston, Texas, 77030, United States
United Hospital

Saint Paul, Minnesota, 55102, United States
United Hospital Center

Bridgeport, West Virginia, 26330, United States
University Hospitals Parma Medical Center

Parma, Ohio, 44129, United States
University Hospitals Portage Medical Center

Ravenna, Ohio, 44266, United States
University Hospitals Sharon Health Center

Wadsworth, Ohio, 44281, United States
University Medical Center New Orleans

New Orleans, Louisiana, 70112, United States
University of Arizona Cancer Center-North Campus

Tucson, Arizona, 85719, United States
University of Arizona Cancer Center-Orange Grove Campus

Tucson, Arizona, 85704, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
University of Illinois

Chicago, Illinois, 60612, United States
University of Kansas Cancer Center

Kansas City, Kansas, 66160, United States
University of Kansas Cancer Center - Lee's Summit

Lee's Summit, Missouri, 64064, United States
University of Kansas Cancer Center - North

Kansas City, Missouri, 64154, United States
University of Kansas Cancer Center-Overland Park

Overland Park, Kansas, 66210, United States
University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, 66205, United States
University of Michigan Health - Sparrow Lansing

Lansing, Michigan, 48912, United States
University of Michigan Health - West

Wyoming, Michigan, 49519, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States
University of New Mexico Cancer Center

Albuquerque, New Mexico, 87106, United States
University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States
University of Rochester

Rochester, New York, 14642, United States
University of Tennessee - Knoxville

Knoxville, Tennessee, 37920, United States
University of Utah Sugarhouse Health Center

Salt Lake City, Utah, 84106, United States
Upper Valley Medical Center

Troy, Ohio, 45373, United States
Valley Health System Ridgewood Campus

Ridgewood, New Jersey, 07450, United States
Wesley Medical Center

Wichita, Kansas, 67214, United States
West Michigan Cancer Center

Kalamazoo, Michigan, 49007, United States
West Virginia University Healthcare

Morgantown, West Virginia, 26506, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.